Senior Vice President, Product Strategy and Market Development
Bill Hatfield, Senior Vice President of Product Strategy and Market Development at Karyopharm Therapeutics, is responsible for developing the commercial strategy for oncology therapies, building the commercial team and preparing for the US launch of selinexor as a novel therapy for patients across a broad range of cancers.
Bill has over thirty-five years of industry experience with Bristol Myers, Millennium Pharmaceuticals, Genzyme, Sanofi, and Karyopharm including the past 23 years in the support of the development and launch of cancer therapies.
He lead the development of commercial teams for Velcade in multiple myeloma, Campath for CLL, Clofarabine for Pediatric ALL and adult AML, Fedratinib for myelofibrosis as well as other many other compounds in clinical development for a broad range of solid tumors and hematologic malignancies.
Bill has a marketing degree from the Boston University School of Management.
Senior Vice President, Regulatory Affairs, Quality, and Pharmacovigilance